| Literature DB >> 34343358 |
Antonella Muraro1, Margitta Worm2, Cherry Alviani3, Victoria Cardona4, Audrey DunnGalvin5,6, Lene Heise Garvey7,8, Carmen Riggioni9, Debra de Silva10, Elizabeth Angier11, Stefania Arasi12, Abdelouahab Bellou13,14,15, Kirsten Beyer16, Diola Bijlhout17, Maria Beatrice Bilò18,19, Carsten Bindslev-Jensen20, Knut Brockow21, Montserrat Fernandez-Rivas22, Susanne Halken23, Britt Jensen20, Ekaterina Khaleva3, Louise J Michaelis24,25, Hanneke N G Oude Elberink26, Lynne Regent27, Angel Sanchez28, Berber J Vlieg-Boerstra29, Graham Roberts3,30,31.
Abstract
Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.Entities:
Keywords: adults; anaphylaxis; children; guidelines
Mesh:
Substances:
Year: 2021 PMID: 34343358 DOI: 10.1111/all.15032
Source DB: PubMed Journal: Allergy ISSN: 0105-4538 Impact factor: 14.710